JPWO2020010117A5 - - Google Patents

Info

Publication number

JPWO2020010117A5

JPWO2020010117A5 JP2020573227A JP2020573227A JPWO2020010117A5 JP WO2020010117 A5 JPWO2020010117 A5 JP WO2020010117A5 JP 2020573227 A JP2020573227 A JP 2020573227A JP 2020573227 A JP2020573227 A JP 2020573227A JP WO2020010117 A5 JPWO2020010117 A5 JP WO2020010117A5

Authority

JP

Japan

Prior art keywords

fgf

polypeptide

preparation according

concentration

pharmaceutical preparation

Prior art date

2022-07-12

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims 14
• 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims 14
• 239000000825 pharmaceutical preparation Substances 0.000 claims 13
• QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 8
• 229960003330 pentetic acid Drugs 0.000 claims 8
• 150000001413 amino acids Chemical group 0.000 claims 7
• 239000002253 acid Substances 0.000 claims 5
• 239000002738 chelating agent Substances 0.000 claims 5
• 229920001184 polypeptide Polymers 0.000 claims 5
• 102000004196 processed proteins & peptides Human genes 0.000 claims 5
• 108090000765 processed proteins & peptides Proteins 0.000 claims 5
• 239000008194 pharmaceutical composition Substances 0.000 claims 4
• 229920001223 polyethylene glycol Polymers 0.000 claims 4
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 4
• 229920000053 polysorbate 80 Polymers 0.000 claims 4
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
• 229930006000 Sucrose Natural products 0.000 claims 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 3
• 229940024606 amino acid Drugs 0.000 claims 3
• 150000001768 cations Chemical class 0.000 claims 3
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 3
• 229940068968 polysorbate 80 Drugs 0.000 claims 3
• 238000002360 preparation method Methods 0.000 claims 3
• 239000005720 sucrose Substances 0.000 claims 3
• 230000008033 biological extinction Effects 0.000 claims 2
• 125000002091 cationic group Chemical group 0.000 claims 2
• 206010012601 diabetes mellitus Diseases 0.000 claims 2
• 238000009472 formulation Methods 0.000 claims 2
• 238000000034 method Methods 0.000 claims 2
• 239000000203 mixture Substances 0.000 claims 2
• 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
• 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
• 229940127557 pharmaceutical product Drugs 0.000 claims 2
• 238000004611 spectroscopical analysis Methods 0.000 claims 2
• ZXSBHXZKWRIEIA-JTQLQIEISA-N (2s)-3-(4-acetylphenyl)-2-azaniumylpropanoate Chemical group CC(=O)C1=CC=C(C[C@H](N)C(O)=O)C=C1 ZXSBHXZKWRIEIA-JTQLQIEISA-N 0.000 claims 1
• 206010016654 Fibrosis Diseases 0.000 claims 1
• 239000002202 Polyethylene glycol Substances 0.000 claims 1
• 239000003945 anionic surfactant Substances 0.000 claims 1
• 239000007853 buffer solution Substances 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
• 230000000694 effects Effects 0.000 claims 1
• 230000004761 fibrosis Effects 0.000 claims 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 230000003204 osmotic effect Effects 0.000 claims 1
• 230000002265 prevention Effects 0.000 claims 1
• 238000007920 subcutaneous administration Methods 0.000 claims 1
• 208000024891 symptom Diseases 0.000 claims 1